Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a heart scan predict who will get better? new study aims to find out

NCT ID NCT07243119

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 180 adults newly diagnosed with heart failure and a weak heart pump. Researchers use multiple types of heart scans and tests to see if they can predict whose heart function will improve over 3-12 months. A smaller part of the study tests a higher dose of a drug (adenosine) to see if it gives clearer images during a PET scan. The goal is to better understand heart recovery and improve personalized care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Capable and has provided written informed consent * LVEF ≤ 40% by echocardiography in connection with hospitalization for heart failure or in connection with outpatient evaluation for heart failure Exclusion Criteria: * Previous diagnosis of heart failure * Unable to understand the patient information * Pregnancy, as the study involves ionizing radiation. * Current severe valvular disease (as defined by the Danish national treatment guidelines on cardio.dk) * Atrial fibrillation with a heart rate \> 130 beats per minute during the inclusion echocardiography * Cardiac surgery within 6 months prior to inclusion * Acute exacerbation of existing chronic obstructive pulmonary disease * Severe asthma or chronic obstructive pulmonary disease with FEV1 \< 1L * any contraindication for adenosine stress testing * Severe renal failure \< 15 mL/min/1.73m² or dialysis * Advanced liver disease (Child-Pugh class C) * Endocarditis at inclusion/baseline * Isolated right-sided heart failure * Malignant disease treated with chemotherapy or radiotherapy, or expected life expectancy under 1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Clinic of Cardiovascular Reseach

    Herning, 7400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.